Ruslan Magomedovich Kabardaev

Ruslan Magomedovich Kabardaev

Auto-generated profile, based on publicly available information

Ruslan Magomedovich Kabardaev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2021 in Bone and soft tissue sarcomas, tumors of the skin
Verified
Journal Article
Open access
PDF file
ATAnastasia Tararykova
Anastasia Tararykova
AFA. A. Fedenko
A. A. Fedenko
EME. R. Musaev
E. R. Musaev
ESE. A. Sushentcov
E. A. Sushentcov
Denis SofronovDenis Sofronov
Denis Sofronov
ASA. V. Sokolovskii
A. V. Sokolovskii
Background. The standard treatment for giant-cell tumors of the bone includes radical surgery. However, specific anatomical location of the tumor and/or its spread may hinder its complete excision or result in poor functional outcomes. Currently, combination treatment that includes preoperative denosumab and surgery is preferable. It saves patients’ lives and improves their quality of life. Reduction of local recurrence rate by combination therapy for giant-cell tumors of the bone is being actively studied now.Objective – to analyze treatment outcomes of patients with giant-cell tumors of the bone, including those who received combination treatment that included preoperative therapy with denosumab followed by surgery.Materials and methods. This study included 277 patients with giant-cell tumors treated in N.N. Blokhin National Cancer Research Center between 2005 and 2020. The mean duration of follow-up was 56 months. Study participants were divided into two groups. Group 1 included patients who received surgical treatment alone (n = 212), whereas Group 2 comprised patients who received combination treatment (n = 65). Neoadjuvant therapy included subcutaneous denosumab 120 mg on days 1, 8, 15, and 28, then every 4 weeks until stable effect. There were two variants of surgical treatment: radical (removal by a single block or segmental resection with defect replacement, with or without fixation) and non-radical (excochleation or marginal resection with defect replacement, with or without fixation).Results. During treatment, patients in Group 2 had a significantly milder pain syndrome (assessed both using the visual analog scale for pain and Watkins scale) compared to Group 1. In case of radical surgery, the incidence of local recurrence was 12 % and 0 % in Groups 1 and 2, respectively; the difference was significant (р 0.05). Tumor location and volume of surgery played an important role in disease recurrence (р 0.05). The incidence of complications after radical surgery was 36.9 % and 12.5 % in Groups 1 and 2, respectively; the difference was significant (р 0.05). In addition to that, neoadjuvant therapy with denosumab substantially reduced the duration of surgery and blood loss in patients with challenging anatomical location of the tumor (р 0.05).Conclusion. Combination treatment for giant-cell tumors that includes neoadjuvant therapy with denosumab reduces the risk of recurrence, duration of surgery, blood loss, and the risk of postoperative complications. However, it is important to consider tumor location and the volume of surgery. Since the disease is quite rare, further study of long-term efficacy and safety of combination treatment for giant-cell tumors, including rare ones and those with challenging anatomical location, is necessary.

28 August 2021 in Bone and soft tissue sarcomas, tumors of the skin
Verified
Journal Article
Open access
PDF file
RKR. M. Kabardaev
R. M. Kabardaev
EME. R. Musaev
E. R. Musaev
AVA. K. Valiev
A. K. Valiev
KBK. A. Borzov
K. A. Borzov
SKS. F. Kuznetsov
S. F. Kuznetsov
AAA. T. Abdulzhaliev
A. T. Abdulzhaliev
Introduction. Radical surgical resections in the treatment of malignant tumors of the spine have proven effective in improving both overall and disease-free survival of patients. Indications for such interventions are primary malignant tumors of the spine, primary benign tumors with aggressive growth, and solitary metastatic lesions in patients with a favorable oncological prognosis. Due to the anatomical features of the vertebral column, it is very difficult to perform radical resections. An even more difficult task is to perform such interventions for multilevel spinal lesions.The study objective is to evaluate the results of radical surgical treatment for multilevel tumor lesions of the spine.Materials and methods. From 2004 to 2019, in the department of spine surgery of the N.N. Blokhin National Medical Research Center of Oncology treated 36 patients with spinal tumors, who underwent multilevel radical resections. The analysis of this surgical treatment of patients with multilevel neoplastic lesions of the spine was carried out.Results. Performing radical surgical interventions on the spine makes it possible to reduce the frequency of local relapses, improve functional results and overall survival of patients. After performing multilevel resections, complications often occur.

23 December 2021 in Russian Journal of Spine Surgery (Khirurgiya Pozvonochnika)
Verified
Journal Article
Open access
PDF file
ATAnastasia Tararykova
Anastasia Tararykova
AFAleksandr Aleksandrovich Fedenko
Aleksandr Aleksandrovich Fedenko
EMElmar Rasimogly Musaev
Elmar Rasimogly Musaev
AVAslan Kamraddinovich Valiev
Aslan Kamraddinovich Valiev
RKRuslan Magomedovich Kabardaev
Ruslan Magomedovich Kabardaev
VMValeria Igorevna Melnikova
Valeria Igorevna Melnikova
Objective. To assess the effect of the combined treatment method including preoperative denosumab therapy on the results of treatment of patients with giant cell tumors of the spine.Material and Methods. A single-center retrospective-prospective study of a series of clinical cases included 15 patients with giant cell tumors of vertebrae. The average follow-up period was 56 months. A total of 11 patients received denosumab therapy according to the following scheme: 120 mg subcutaneously on the 1st, 8th, 15th and 28th days of the first month and then once every 28 days. Surgical options included marginal resection, segmental resection, or en-bloc resection with or without spinal reconstruction/stabilization. In the case of locally advanced and inoperable disease, long-term therapy with denosumab was carried out until the disease progressed or serious adverse events appeared.Results. Thoracic vertebrae were involved in 7 (46.6 %) of 15 cases, lumbar in 4 (26.7 %) and cervical in 4 (26.7 %). Local recurrence rate after surgery alone was 40 % (2/5), average time to recurrence onset was 4.5 months. No relapses were observed after combined treatment performed in four patients. Disease progression during long-term denosumab therapy for inoperable disease recurrence was not recorded (0/7). The average number of denosumab injections before surgery and during long-term therapy was 15 and 24 injections, respectively. Denosumab therapy allows reducing the duration of surgery and the volume of blood loss.Conclusion. Combined therapy of giant cell vertebral tumor allows to reduce the risk of recurrence of the disease, as well as to reduce surgery duration and blood loss. Long-term continuous therapy for inoperable cases allows achieving long-term stabilization of the effect. Due to the rarity of giant cell tumors of the spine, a further prospective recruitment of patients is required to study the efficacy and safety of combined therapies.

18 December 2023 in Bone and soft tissue sarcomas, tumors of the skin
Verified
Journal Article
Open access
PDF file
ATAnastasia Tararykova
Anastasia Tararykova
AVA. K. Valiev
A. K. Valiev
PKP. V. Kononets
P. V. Kononets
ECE. R. Charchyan
E. R. Charchyan
RKR. M. Kabardaev
R. M. Kabardaev
NKN. A. Kozlov
N. A. Kozlov
Introduction. Primary spinal osteosarcoma and rare metastatic heart lesion are considered significant factors for poor prognosis. The available work indicates that combined treatment, including the radical surgery of heart solitary metastatic lesion, probably provides the best outcome.Case report. Man, 27-year-old, with Th8 spinal osteosarcoma and solitary left atrial metastasis. From October 2019 to February 2020 5 cycles of chemotherapy (high doses of platinum and doxorubicin) were carried out with positive effect. Next steps were surgery: March 2020 – spondylectomy of the Th8 vertebra with combined stabilization; September 2020 – subtotal resection with plasty of the right atrium, tricuspid valve and prosthesis of the right coronary artery. Between the first and second surgery, 4 more same chemotherapy cycles were carried out. Currently, 24 months after completion of treatment, there are no signs of the disease.Conclusion. The article presents a unique case of treatment of primary osteosarcoma and metastatic lesion of rare location. Multidisciplinary approach and combination treatment in specialized centers increase the probability of favorable outcome in such cases.

6 August 2025 in Cancer Urology
Verified
Journal Article
Open access
PDF file
AKA. V. Klimov
A. V. Klimov
AKA. O. Karyakin
A. O. Karyakin
NDN. Ts. Drobot
N. Ts. Drobot
EGE. O. Gazaryan
E. O. Gazaryan
RKR. M. Kabardaev
R. M. Kabardaev
SAS. V. Averianova
S. V. Averianova
Renal cell carcinoma (RCC) are among the most frequently diagnosed types of cancer in the world. Despite improvements in diagnostics in the recent years, every third patient with RCC is still diagnosed at the metastatic stage, which explains high mortality rates with this pathology. RCC is a heterogeneous disease. At the stage of metastatic process, factors including presence and site of metastases, prior nephrectomy before systemic therapy, and sarcomatoid differentiation based on the pathomorphological study are most important in determining treatment tactics.In the era of cytokine therapy, patients with metastases were treated with cytoreductive nephrectomy as a first step, as demonstrated in the SWOG and EORTC trials. Currently, the National Comprehensive Cancer Network (NCCN) Guidelines, European Society for Medical Oncology (ESMO) Guidelines, and American Urological Association (AUA) Guidelines suggest a more selective approach to cytoreductive nephrectomy in patients with metastatic RCC and selection of patients for surgery according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria. And for poor prognosis group, preference should be given primarily to dual immune or immune-targeted systemic therapy. Surgical intervention is reserved for patients with not more than 3 factors, with “low metastatic load”, and good performance status.This publication describes a clinical case of successful treatment of a 58-year-old patient with metastatic RCC (T3bN1M1) and poor prognosis according to the IMDC criteria. The patient had no prior history of nephrectomy and presented with a venous tumor thrombus of the right renal vein and the inferior vena cava up to the level of the caval porta, along with metastases to the liver and the 10th thoracic vertebra.The combination of lenvatinib and pembrolizumab was selected as first-line therapy and administered from February 2023 to March 2025 (25 months of treatment).After 3 months of lenvatinib plus pembrolizumab treatment, the tumor thrombus showed reduction (began to be washed by blood), and disease regression was reported in the form of a 60 % reduction in target lesions per the RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) criteria. Most notably, the liver metastasis demonstrated a remarkable decrease from 7 cm to 2 cm (78 % reduction), which was achieved with the therapy conducted. The tumor of the right kidney exhibited a 50 % size reduction (from 10 cm to 5 cm), accompanied by decreased contrast enhancement in the aortic phase on imaging.

23 June 2024 in Bone and soft tissue sarcomas, tumors of the skin
Verified
Journal Article
Open access
PDF file
SKS. F. Kuznetsov
S. F. Kuznetsov
NBN. S. Babkin
N. S. Babkin
RKR. M. Kabardaev
R. M. Kabardaev
KBK. A. Borzov
K. A. Borzov
DSD. I. Sofronov
D. I. Sofronov
AVA. K. Valiev
A. K. Valiev
Osteoid osteoma is a rare benign osteogenic bone tumor without malignant potential causing severe night pain relieved by nonsteroidal anti-inflammatory drugs. Pain associated with osteoid osteoma of the spine cannot be treated conservatively and requires surgical approach. Types of surgical treatment include intralesional curettage, marginal resection, or en bloc tumor resection. However, absence of clear intraoperative visualization of the lesion often leads to excessive resection of vertebral structures requiring additional bone reconstruction and fixation with metal structures. In some cases, due to incorrect choice of resection area and segment level, repeat surgeries are performed causing secondary spinal deformations, worsening patient’s condition, and increasing economic expenditures. Currently, minimally invasive methods of transcutaneous treatment of osteoid osteomas such as interstitial laser ablation, cryotherapy, and radiofrequency thermal ablation are becoming more prominent.Aim. To evaluate the effectiveness of radiofrequency thermal ablation treatment in patients with osteoid osteoma.Materials and methods. The prospective study included 12 patients with osteoid osteoma of the spine. Their quality of life was evaluated using the Short Form-36 (SF-36) questionnaire prior to radiofrequency thermal ablation and 30, 90 and 180 days after. At the first visit and during observation, pain syndrome intensity was measured using the Visual Analog Scale (VAS) and R.G. Watkins scale for objective evaluation of pain syndrome per number of analgesics administrations.Results. Follow-up duration varied between 12 and 36 months. In all clinical cases, general, physical, and psychological health improved 2–3-fold. Pain intensity at day 1 after radiofrequency thermal ablation compared to mean pain intensity during the day prior to the procedure was significantly lower (р = 0.05). At the final examination, none of the patients had pain (pain syndrome intensity 0 per VAS); all patients had subjective satisfaction level of 100 %. Analgesics (nonsteroidal anti-inflammatory drugs and paracetamol) were administered on request for 8 ± 2.34 days after the procedure.Conclusion. Based on literature data and our own experience of diagnosis and surgical treatment of osteoid osteoma of the spine, we conclude that in cases of small lesions (2 cm) in hard to access locations, computed tomography-controlled radiofrequency thermal ablation allows to perform surgical intervention safely, effectively and with minimal number of complications.